Abstract
Introduction: Until recently, there have been limited options for treatment of metastatic neuro endocrine tumors (NETs). Real life experience with newly developed targeted therapies for this condition is limited outside large referral centers.
Case: Here we describe a 43 year old patient with metastatic NET of intestinal origin. The management of this patient illustrates a number of real life practical issues including effect of treatment interruption, secondary resistance to somatostatin analogues, availability and toxicity of new targeted agents, multiple lines of sequential treatment and local availability of specific investigations. This patient is enjoying a long progression free survival (29+ months) on a combination of Everolimus and Octreotide-LAR with a survival of 43+ months from diagnosis of metastatic disease.
Conclusion: Patient with metastatic NETs can benefit from newly developed targeted therapies. However, they are best managed by multi-disciplinary teams in referral centers to guarantee adequate experience and specialist resources.
Keywords: Neuroendocrine, targeted therapy, Octreotide-LAR, Everolimus, Sunitinib, multi-disciplinary.
Current Cancer Therapy Reviews
Title:Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success
Volume: 9 Issue: 3
Author(s): Jamal Zekri and Zahid Amin Khan
Affiliation:
Keywords: Neuroendocrine, targeted therapy, Octreotide-LAR, Everolimus, Sunitinib, multi-disciplinary.
Abstract: Introduction: Until recently, there have been limited options for treatment of metastatic neuro endocrine tumors (NETs). Real life experience with newly developed targeted therapies for this condition is limited outside large referral centers.
Case: Here we describe a 43 year old patient with metastatic NET of intestinal origin. The management of this patient illustrates a number of real life practical issues including effect of treatment interruption, secondary resistance to somatostatin analogues, availability and toxicity of new targeted agents, multiple lines of sequential treatment and local availability of specific investigations. This patient is enjoying a long progression free survival (29+ months) on a combination of Everolimus and Octreotide-LAR with a survival of 43+ months from diagnosis of metastatic disease.
Conclusion: Patient with metastatic NETs can benefit from newly developed targeted therapies. However, they are best managed by multi-disciplinary teams in referral centers to guarantee adequate experience and specialist resources.
Export Options
About this article
Cite this article as:
Zekri Jamal and Khan Amin Zahid, Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success, Current Cancer Therapy Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573394709666131108210254
DOI https://dx.doi.org/10.2174/1573394709666131108210254 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
Current Neuropharmacology Pericytes Within A Pulmonary Neurovascular Unit in Coronavirus Disease 2019 Elicited Pathological Changes
Current Neurovascular Research Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction
Current Pharmaceutical Design Factors Influencing the Hemodynamic and Metabolic Effects of Insulin in Muscle
Current Diabetes Reviews Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research Transforming Growth Factor-Beta Family: Advances in Vascular Function and Signaling
Current Protein & Peptide Science The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Current Pharmaceutical Design Controversial Issues of Abortion License According to Religious and Jurisprudential Laws in Iran: A Systematic Review
Current Women`s Health Reviews Integration and Querying of Heterogeneous Omics Semantic Annotations for Biomedical and Biomolecular Knowledge Discovery
Current Bioinformatics Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research The Need for an Interdisciplinary Network of Investigations on HHT
Current Pharmaceutical Design Understanding the Role and Mechanism of Carbonic Anhydrase V in Obesity and its Therapeutic Implications
Current Protein & Peptide Science Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Formulation and Characterization of Gliclazide Oral Dissolving Films
Drug Delivery Letters Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism